In fact, the baseline expression of TG2 is under the transcription regulation of NF-κB in cultured breast cancer cells, because pharmacological inhibition or knockdown of NF-κB resulted in a significant diminishment in TG2 expression in MCF-7/DOX and MDA-MB-231 cells (Ai et al., 2012). This evidence concerns the gene NFKB1 and breast cancer.